Israel -
Ibrani -
Ministry of Health
דיספורט 500
medison pharma ltd - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 500 u/vial - botulinum toxin
Israel -
Ibrani -
Ministry of Health
טרנדייט טבליות 100 מג
padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.
Israel -
Ibrani -
Ministry of Health
היקמטין 0.25 מג
novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.
Israel -
Ibrani -
Ministry of Health
תחליב המכיל פקטורי גדילה ( egf+igf ) ואלסטין
ביוטי פלוס בעמ - צמצום קמטים וקמטוטים
Israel -
Ibrani -
Ministry of Health
ג'ארדיאנס 10 מג
boehringer ingelheim israel ltd. - empagliflozin - טבליות מצופות פילם - empagliflozin 10 mg - linagliptin and empagliflozin
Israel -
Ibrani -
Ministry of Health
ג'ארדיאנס 25 מג
boehringer ingelheim israel ltd. - empagliflozin - טבליות מצופות פילם - empagliflozin 25 mg - linagliptin and empagliflozin
Israel -
Ibrani -
Ministry of Health
קימריה
novartis israel ltd - tisagenlecleucel - tisagenlecleucel
Israel -
Ibrani -
Ministry of Health
פולבסטרנט סנדוז
novartis israel ltd - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant
Israel -
Ibrani -
Ministry of Health
טרקליר 62.5 מג
j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
Israel -
Ibrani -
Ministry of Health
טרקליר 125 מג
j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease